UDK 616.94-085
COBISS.SR-ID 33162505

ISSN 0350-2899. - Vol. 45, br. 4 (2020), str. 153-158.

ZNAČAJ HEMODINAMSKE STABILIZACIJE I ADJUVANTNE TERAPIJE U LEČENJU PACIJENATA SA SEPSOM I SEPTIČNIM ŠOKOM

Vesna Marjanović (1,2), Ivana Budić (1,2), Saša Ignjatijević (3), Marija Stević (4,5), Dušica Simić (4,5)

(1) UNIVERZITET U NIŠU, MEDICINSKI FAKULTET U NIŠU; (2) KLINIKA ZA ANESTEZIJU I INTENZIVNU TERAPIJU UKC NIŠ; (3) ZAVOD ZA HITNU MEDICINSKU POMOĆ NIŠ; (4) UNIVERZITET U BEOGRADU, MEDICINSKI FAKULTET U BEOGRADU; (5) UNIVERZITETSKA DEČJA KLINIKA TIRŠOVA

Sažetak: Sepsa predstavlja po život-opasno kliničko stanje, koje zahteva rano prepoznavanje, detaljnu početnu procenu i brzu primenu terapijskih postupaka. Dosadašnje preporuke iz 2016. godine u lečenju sepse su ukazale na važnost rane inicijalne nadoknade tečnosti, kontrole izvora infekcije, procene laboratorijskih parametara i preciznijeg monitoring hemodinamskog statusa septičnih pacijenata unutar 3 do 6 sati od dijagnostikovanja sepse sa ciljem poboljšanja njihovog krajnjeg ishoda. Poslednja revizija u lečenju sepse evidentirana 2018. godine ukazuje da svi postupci u lečenju moraju biti primenjeni unutar jednog sata od dijagnostikovanja sepse. Urgentna nadoknada tečnosti, dominantno izotonih slanah ili balansiranih kristaloidnih rastovora u volumenu od 30 ml/kg obezbeđuje adekvatnu hemodinamsku stabilnost septičnih pacijenata. U slučaju da se ordiniranim tečnošću ne može obezbediti hemodinamska stabilnost i zadovoljavajući srednji arterijski pritisak (> 65 mm Hg), potrebno je primeniti vazopresore. Najpoželjniji vazopresor za septične pacijente je norepinefrin, koji se može primeniti ponaosob ili u kombinaciji sa drugim vazopresorima poput epinefrina, vazopresina, terlipresina ili fenilefrina. Pored toga, septični pacijenti sa neadekvatnim minutnim volumenom srca nakon nadoknade tečnosti, sepsa-indukovanom kardiomiopatijom ili kombinovanim šokom, zahtevaju često primenu inotropnih lekova, epinefrina i dobutamina. Adjuvantna terapija poput kortikosteroida, imunoglobulina, antikoagulantne terapije, statina, primene vitamina C i B1, pokazuju izvestan benefit u lečenju septičnih pacijenata, ali njihova primena nije pokazala veliku prednost u poboljšanju krajnjeg ishoda ovih pacijenata. Zaključuje se da rano dijagnostikovanje sepse i septičnog šoka unutar jednog sata, adekvatna nadoknada tečnosti i primena vazoaktivnih lekova u cilju bržeg postizanja hemodinamske stabilnosti, može biti presudno u obezbeđivanju boljeg ishoda ovih pacijenata.

Ključne reči: sepsa, nadoknada tečnosti, vazoaktivni lekovi, adjuvantna terapija, kortikosteroidi, imunoglobulini

Ovaj rad je prezentovan na 6. Međunarodnom kongresu Urgentne medicine u Nišu 23.-25. oktobra 2020. godine pod naslovom "Hemodinamska stabilizacija i adjuvantna terapija kod septičnih pacijenata".

UVOD

Sepsa predstavlja urgentno medicinsko stanje uzrokovano neadekvatnom odbranom organizma na infekciju. Septični šok podrazumeva cirkulatorne, ćelijske i metaboličke poremećaje kod septičnih pacijenata, koji se prezentuje hipotenzijom rezistentnom na učinjenu nadoknadu tečnosti i potrebom za vazopresornom terapijom [1]. Oba klinička stanja zahtevaju rano prepoznavanje, detaljnu početnu procenu i brzu primenu terapijskih postupaka kako bi se smanjio stepen smrtnosti ovih pacijenata. Dosadašnje preporuke u lečenju sepse iz 2016. godine su

ukazale na važnost rane inicijalne nadoknade tečnosti, kontrole izvora infekcije, procene laboratorijskih parametara i preciznijeg monitoring hemodinamskog statusa pacijenata u cilju poboljšanja njihovog krajnjeg ishoda. Takođe se smatralo da je merenje laktata, uzimanje hemokulture pre ordiniranja antibiotika, ordiniranje antibiotika širokog spektra, brza nadoknada kristaloida 30ml/kg i primena vazopresora kod pacijenata rezistentnih na nadoknadu tečnosti, neophodno sprovesti unutar 3 do 6 sati od dijagnostikovanja sepse [2]. Poslednje promene u lečenju sepse evidentirane su 2018. godine kada se zaključilo

Adresa autora: Vesna Marjanović, Univerzitet u Nišu, Medicinski fakultet u Nišu; Klinika za anesteziju i intenzivnu terapiju KC NIŠ

E-mail: drvesnamarjanovic@gmail.com

Rad primljen: 01.02.2021. Elektronska verzija objavljena: 08.03.2021.

www.tmg.org.rs

IMPORTANCE OF HAEMODYNAMIC STABILITY AND ADJUVANT THERAPY IN THE TREATMENT OF PATIENTS WITH SEPSIS AND SEPTIC SHOCK

Vesna Marjanović (1,2), Ivana Budić (1,2), Saša Ignjatijević (3), Marija Stević (4,5), Dušica Simić (4,5)

(1) UNIVERZITET U NIŠU, MEDICINSKI FAKULTET U NIŠU; (2) KLINIKA ZA ANESTEZIJU I INTENZIVNU TERAPIJU UKC NIŠ; (3) ZAVOD ZA HITNU MEDICINSKU POMOĆ NIŠ; (4) UNIVERZITET U BEOGRADU, MEDICINSKI FAKULTET U BEOGRADU; (5) UNIVERZITETSKA DEČJA KLINIKA TIRŠOVA

Summary: Sepsis represents a life-threatening condition that requires prompt recognition, detailed initial assessment and energetic administration of therapy. Guidelines published in 2016 emphasized the importance of early fluids replacement and infection control together with assessment based on laboratory parameters and precise monitoring of hemodynamic status of septic patients within the first 3-6 hours after diagnosis. Revision that followed in 2018 stressed that all therapeutic actions should be initiated within the first hour after diagnosis. Urgent administration of isotonic saline and balanced crystalloids in a dose of 30ml/kg should provide adequate hemodynamic stability of septic patients. If the fluid replacement fails to achieve hemodynamic stability and mean arterial pressure >65 mmHg, addition of vasopressors is mandatory. The vasopressor of choice for septic patients is norepinephrine. It may be used alone or in combination with other vasopressors such as epinephrine, vasopressin, terlipressin or phenylephrine. Septic patients with inadequate cardiac output after fluid replacement, and cardiomyopathy induced by sepsis or those with combined shock may need treatment with inotropic medication such as epinephrine or dobutamine. Adjuvant therapy with steroids, immunoglobulins, anticoagulants, statins, vitamin C and B1, may be useful, but no benefit regarding the overall outcome was observed. In conclusion, early detection of sepsis and septic shock within the first hour and immediate adequate fluid administration with vasoactive medications to maintain hemodynamic stability, are crucial for achievement of better outcome of these patients.

Key words: sepsis, fluid replacement, vasoactive drugs, adjuvant therapy, corticosteroids, immunoglobulins

This paper was presented on the 6th International congress of Serbian Society of Emergency Physicians held in Nis, from 23-25. 2020, entitled: Hemodynamic Stabilization and Adjuvant Therapy in a Septic Patient”.

INTRODUCTION

Sepsis is urgent medical condition caused by inadequate immune response to infection. Septic shock encompasses circulatory, cellular and metabolic disorders presented as hypotension resistant to fluid replacement with urgent need for vasopressor therapy [1]. Early recognition of these conditions, detailed initial estimation and prompt therapy are of primary importance for reduction of death rate in sepsis. Guidelines published in 2016, underlined the importance of early fluid supplementation and control of the source of infection. Furthermore, appropriate laboratory estimation and hemodynamic monitoring are crucial for improvement of treatment outcome. This literally implies lactate level measurement, hemoculture sampling before administration of

antibiotics, preferred use of broad-spectrum antibiotics and rapid crystalloid supplementation in the dose of 30ml/kg. In hypotensive cases resistant to fluid replacement, vasopressors should be given within 3 - 6 hours since diagnosis was made [2]. The latest recommendations for treatment of sepsis from 2018 have confirmed all treatment modalities published in 2016 with the update concerning the timing of treatment initiation. The new recommendation stressed that treatment should be initiated and rapidly administrated within the first hour after diagnosis of sepsis [3]. The shift in timing needs reconsideration of fluid replacement intensity and dynamics, appropriate and timely vasopressor administration as well as the use of adjuvant

da svi navedeni elementi preporuke iz 2016. godine moraju biti započeti ili većim delom završeni unutar jednog sata od dijagnostikovanja sepse [3]. Usled nastalih promena u terapijskim postupcima sepse, neophodno je razmotriti važnost nadoknade tečnosti, vazopresora i adjuvantne terapije u stabilizaciji hemodinamskih parametara i poboljšanju krajnjeg ishoda pacijenata sa sepsom i septičnim šokom.

NADOKNADA TEČNOSTI, PROCENA HEMODINAMSKE STABILNOSTI I PRIMENA VAZOAKTIVNIH LEKOVA KOD SEPTIČNIH PACIJENATA

Sepsa kao životno-ugrožavajuće medicinsko stanje je povezana sa generalizovanim endotelnim oštećenjem, povećanom kapilarnom permeabilnošću, smanjenim cirkulišućim volumenom krvi i prilikom krvi u desno srce. Ovi hemodinamski efekti imaju za posledicu smanjenu tkivnu perfuziju i organsku disfunkciju. Cilj reanimacionih postupaka kod sepse i septičnog šoka je obnoviti cirkulišući volumen krvi, povećati isporuku kiseonika tkivima i smanjiti ili eliminisati sepsom uzrokovana organska oštećenja. Preporuka je da se nadoknada tečnosti mora započeti bolusima kristaloida u volumenu od 30 ml/kg unutar prvog, a završiti unutar trećeg sata od dijagnostikovanja sepse ili septičnog šoka [2].

Nadoknada tečnosti se kod septičnih pacijenata odvija unutar 4 faze:

- Faza spašavanja započinje unutar par minuta do par sati od dijagnoze sepse kod životno-ugroženih pacijenata sa znacima dekompenzovanog šoka (snižen krvni pritisak, znaci smanjene tkivne perfuzije), kada se ordinira tečnost u volumenu od 30 ml/kg kristaloida
- Faza optimalizacije, podrazumeva septičnog pacijenata, koji nije više u neposrednoj životnoj opasnosti već u stanju kompenzovanog šoka. Ordiniranje dodatnih količina tečnosti je opreznije i titrira se do optimalizacije minutnog volumena srca i tkivne perfuzije kao i izbegavanja neželjenih efekata hipervolemije.
- Faza stabilizacije, se dešava unutar 24 do 48 sati od dijagnoze sepse, pacijent je stabilnog opšteg stanja, a ordinirane

tečnosti su dovoljne da kupiraju standardne bubrežne, gastro-intestinalne ili nejasne gubitke tečnosti. Pacijenti nisu u stanju šoka, kao ni u neposrednoj opasnosti od šoka.

- Faza de-eskalacije se karakteriše odsustvom šoka kod pacijenata i oporavkom svih organskih funkcija, a ordiniranje tečnosti se primenjuje u cilju obezbeđivanja net-neutralnog ili lagano negativnog balansa tečnosti. Time se izbegava nepotrebno jatrogeno preopterećenje tečnostima [4,5].

Za inicijalnu nadoknadu tečnosti, u fazi spašavanja, predlažu se izotoni slani ili balansirani kristaloidni rastvorovi, pri čemu se u poslednjih 10 godina posebno favorizuje primena balansiranih kristaloida (rastvor Ringera i Ringer-laktata). Primenom izotoničnih slanih rastvora češća je pojava hiperhloremične i metaboličke acidoze, koja izaziva renalnu vazokonstrikciju i redukuje protok krvi kroz korteks bubrega. Suprotno izotoničnim rastvorima, primenom balansiranih rastvora uočena je manja incidenca bubrežnih oštećenja, hemodijalize i smrtnosti kritično-obojele pacijenata [6,7,8]. Iako se klinička primena koloida može opravdati porastom onkotskog pritiska, redukovanjem kapilarne propustljivosti i količine ordinirane tečnosti, njena primena nije pokazala bolji ishod pacijenata sa sepsom i septičnim šokom. Tako primenom albumina u inicijalnoj reanimaciji septičnih pacijenata nije uočen benefit njegove primene u odnosu na ostale kristaloide osim u većoj ceni lečenja [9]. Takođe se ne preporučuje primena ni ostalih koloida, poput hidroksietil skroba, koji je povezan sa većom smrtnošću i bubrežnom insuficijencijom septičnih pacijenata [10].

Cilj svake nadoknade tečnosti je održati srednji arterijski pritisak (MAP) iznad 65 mm Hg i obezbediti adekvatnu perfuziju tkiva. Sa ordiniranjem velike količine tečnosti radi postizanja zadovoljavajućeg MAP, moguće je volumensko preopterećenje septičnih pacijenata. Ono se može manifestovati nastankom plućnog edema, hipoksemične respiratorne insuficijencije, edema perifernih tkiva, intra-abdominalne hipertenzije, produženim boravkom u Jedinici intenzivne nege (JIN) i većom smrtnošću ovih pacijenata [4,11]. Zbog toga je potrebno kontinuirano procenjivati volumenski status septičnih pacijenata merenjem statičkih parametara

therapy, which is going to be discussed in the following review.

FLUID REPLACEMENT, HEMODYNAMIC STABILITY ESTIMATION, AND THE USE OF VASOACTIVE DRUGS IN SEPTIC PATIENTS

Sepsis is a life-threatening condition associated with generalized endothelial damage, increased capillary permeability, decreased circulatory blood volume and decreased preload into the right atrium. These hemodynamic effects result into decreased tissue perfusion and organ dysfunction. One of the main goals in reanimation of septic patient is to renew circulatory blood volume and normalize oxygen delivery to tissues that is the prerequisite for improvement and elimination of organ damage. It is recommended to initiate fluid supplementation with crystalloid boluses within first hour in dose of 30 ml/kg. Dose should be completely administered within third hour after the sepsis or septic shock diagnosis [2].

Fluid supplementation in septic patients is usually performed in four phases:

- Rescue phase: initiated within few minutes, lasting for a few hours after diagnosis in cases with life-threatening decompensated shock (low blood pressure, signs of decreased tissue perfusion). The volume of given crystalloids should be 30 ml/kg.
- Optimization phase: is applicable for a patient with sepsis in a state of compensated shock, whose life is not immediately endangered. Administration of additional volume of fluids is more cautious and should be titrated until achievement of optimal cardiac output and tissue perfusion. Undesirable hypervolemia should be avoided in this phase.
- Stabilization phase usually occurs within 24-48 hours after diagnosis, with patient being in good general condition. Volume of administered fluid should be enough to compensate standard renal, gastro-intestinal or other unclear fluid losses. Patients are neither in the state of shock, nor in immediate danger to develop this condition.
- De-escalation phase is characterized by absence of shock in patient and by recovery of all organ functions. Fluids should be given in order to provide net-

neutral or slightly negative fluid balance. In this way, iatrogenic unnecessary fluid overload is be avoided [4,5].

For initial fluid replacement, in rescue phase, recommendations are in favor for isotonic salt or balanced crystalloids solutions. In the last 10 years, Ringer or Ringer-lactate solutions are considered advantageous. If non-balanced isotonic solutions are administered, hyperchloremic and metabolic acidosis is more likely to occur, with consecutive renal vasoconstriction and blood flow reduction through the renal cortex. If balanced solutions are used, renal insufficiency may develop less frequently with less need for dialysis and with decreased mortality in critically ill patients [6,7,8]. The clinical use of colloids was sometimes justified by the need to improve low oncotic pressure or to reduce capillary leakage or in some cases with the idea to reduce excessive fluid volume replacement. Unfortunately, the use of colloids showed no advantage over balanced crystalloids in sepsis and septic shock. Furthermore, no benefit was seen when albumins were administered during initial reanimation comparing to balanced crystalloids and the treatment cost was higher in this group of patients [9]. Other colloids such as hydroxyethyl starch are also not recommended in sepsis, since their use was associated with renal insufficiency and increased mortality [10].

The goal of every fluid replacement strategy is to maintain median arterial pressure (MAP) above 65 mm Hg thus providing adequate tissue perfusion. While attempting to achieve desirable MAP, it is often possible to cause volume overload if large volumes of fluids are given. State of overload is manifested by pulmonary oedema, hypoxemic respiratory insufficiency, swelling of peripheral tissue, development of intrabdominal hypertension with prolonged duration of stay in intensive care (ICU) and higher death rate [4,11]. For this reason, continuous estimation of fluid volume status is mandatory through the measurement of both static (median arterial pressure, central-venous pressure, hourly urine output) and dynamic parameters. Static parameters have shown considerable inferiority comparing to dynamic measures for prediction of volume overload [12,13,14]. Also, dynamic parameters enabled more appropriate fluid replacement, affecting positively the cardiac output,

(srednjeg arterijskog pritiska, centralno-venskog pritiska, satne diureze) kao i dinamičkih parametara. Pri tome je uočena značajna slabost statičkih parametara u predviđanju volumenskog preopterećenja septičnih pacijenata u odnosu na dinamičke parametre [12,13,14]. Takođe, sa primenom dinamičkih merenja postignuta je bolja nadoknada tečnosti i pozitivan efekat na minutni volumen srca, kao i kraće trajanje mehaničke ventilacije, boravak u JIN i manja smrtnost ovih pacijenata [15,16,17]. Ova dinamička merenja se sprovode nakon ordiniranja bolusa tečnosti ili pasivnog podizanja nogu, kojim se oko 200 do 300 ml krvi vraća iz donjih ekstremiteta u sistemsku cirkulaciju. Promene u minutnom volumenu srca nastale nakon toga, mogu se meriti direktno (termodilucijom ili ehokardiografijom) ili uočavanjem promena u pulsnom pritisku. Kod pacijenata na mehaničkoj ventilaciji, promene u minutnom volumenu srca se procenjuju kroz varijacije pulsog pritiska, udarnog volumena srca i veličine v.cava inferior tokom inspirijuma i ekspirijuma [16, 17].

Pored dinamičkih merenja, nadoknada tečnosti se u fazi spašavanja može pratiti kroz analizu nivoa laktata i saturacije centralne venske krvi (ScvO₂). Povišene vrednosti laktata tokom sepse mogu nastati usled tkivne hipoksije, ubrzane aerobne glikolize uzrokovane beta-adrenergičkom stimulacijom, uticaja lekovima (epinefrin, β -2 agonisti) ili hepatalne insuficijencije. Merenjem laktata se može objektivno proceniti odgovor pacijenata na postupke resuscitacije kao i predvideti njihov lošiji ishod. To je posebno evidentirano kod septičnih pacijenata sa nivoom laktata iznad 4 mmol/l [18,19]. Ukoliko su vrednosti laktata, kao markera tkivne hipoperfuzije, veće od 2 mmol/l pri inicijalnoj proceni pacijenata, neophodno je ponoviti ova merenja na svaka 2 do 4 sata do normalizacije njegovih vrednosti [19]. Time se može značajno redukovati mortalitet septičnih pacijenata [20,21]. Takođe, postupak nadoknade tečnosti kod ovih pacijenata se može pratiti kroz procenu ScvO₂ i kapilarnog refill-a, mada nije uočen benefit njihovog praćenja u odnosu na nivo laktata [20,22].

Aдекватnim odgovorom septičnih pacijenata na ordiniranu tečnost se smatra, ukoliko je nastala reverzija hipotenzije, porast sistolnog krvnog pritiska iznad 90 mmHg ili MAP iznad 65 mmHg bez uticaja vazopresora. Ipak,

izvestan broj pacijenata ostaje refraktaran na ordiniranu tečnost, što je evidentirano kod 36,2% pacijenata u retrospektivnoj studiji urađenoj na 3686 pacijenata [23]. Zbog refraktarnosti septičnih pacijenata na ordiniranu tečnost, registrovana je prolongirana mehanička ventilacija, boravak u JIN i hospitalizacija kao i veća stopa smrtnosti kod istih. Najčešći razlozi za nastanak refraktarnosti kod pacijenata su: zakasnelo ordiniranje tečnosti nakon inicijalnog prepoznavanja sepse (duže od 2 sata), prisustvo srčane insuficijencije, hipotermije, koagulopatije, imuno-kompromitovani pacijenti, kao i laktati iznad 4 mmol/l pri inicijalnoj proceni pacijenata [23].

Brzo obnavljanje zadovoljavajuće perfuzije tkiva vitalnih organa je osnov reanimacije kritično-oboletih pacijenata i ne sme se odlagati. Ukoliko se inicijalnom nadoknadom tečnosti nije ostvarila adekvatna perfuzija tkiva, moraju se primeniti vazopresori pojedinačno ili u kombinaciji sa inotropima u cilju ostvarivanja MAP većeg od 65 mmHg. Fiziološki efekti vazopresora i inotropa se ogledaju u porastu krvnog pritiska i minutnog volumena srca, što poboljšava isporuku kiseonika tkivima ovih pacijenata. Vazopresore treba titrirati do postizanja željenog MAP, a da se pri tome izbegnu potencijalno neželjeni efekti ovih lekova poput aritmija, ishemije srca, mezenterijuma, cerebrovaskularnog regiona ili perifernih delova tela [24]. Ukoliko se krvni pritisak ne može podići ovim lekovima iznad željenog (MAP>65 mmHg), tkivna perfuzija se linearno smanjuje i uočava značajno smanjenje satne diureze, menja mentalni status i smanjuje klirens laktata [25]. Norepinefrin je vazopresor prvog izbora kao potentan α -adrenergički agonist i manje potentan β -adrenergički agonist. Rana administracija norepinefrina pokazuje veći benefit pri lečenju septičnog šoka u odnosu na ostale vazopresore, obezbeđuje bolju organsku perfuziju i smanjuje rizik od aritmije i redukuje mortalitet ovih pacijenata u odnosu na dopamin [26,27,28]. Sa ranim ordiniranjem norepinefrina (93 vs 192 minuta) postignuta je bolja kontrola septičnog šoka u prvih 6 sati, smanjena je učestalost kardiogenog plućnog edema i novonastalih aritmija u odnosu na kasnije ordiniran norepinefrin [29]. Da bi se ovo iskustvo implementiralo u svakodnevnu kliničku praksu, potrebne su nove studije sa većim stepenom dokaza. Pred norepinefrina, mogu se koristiti dodatni vazopresori poput epinefrina,

shortening duration of mechanical ventilation and ICU stay with the decrease in mortality [15,16,17]. Dynamic measures are performed after administration of bolus fluids or after passive leg elevation. The latter maneuver may return 200 - 300 ml of blood from lower extremities to systemic circulation. Consecutive changes in the cardiac output may be directly measured using thermodilution or echocardiography or by registering changes in pulse pressure. Changes of cardiac output during inspiratory and expiratory phase of mechanical ventilation could be estimated through the variations of the pulse pressure, stroke volume and diameters of v. cava inferior [16,17].

Apart from dynamic measurements, fluid replacement during rescue phase can be assessed through an analysis of lactate levels and central venous oxygen saturation (ScvO₂). Increase in lactate levels during sepsis may result from tissue hypoxia, increased aerobic glycolysis induced by β -adrenergic stimulation, but the increase may also be the result of effects of certain drugs (epinephrine, β_2 agonists) or hepatic insufficiency. Lactate follow up, may objectively estimate response to resuscitation attempts and predict its inferior outcome. This was particularly evidenced in septic patients with lactate levels above 4 mmol/l [18,19]. If serum lactate levels as markers of tissue hypoperfusion are above 2 mmol/l during initial assessment, measurements should be repeated every 2-4 hours until normalization [19]. Therapy driven by the levels of this biomarker, may significantly reduce mortality in septic patients [20,21]. Therapeutic effects of fluid supplementation may also be followed by ScvO₂ and capillary refill assessment, although their follow up was not found to be advantageous, comparing to lactate level analysis [20,22].

Response to supplemented fluid in septic patients is considered adequate if systolic pressure rises above 90 mmHg, in case of hypotension reversion or when MAP reaches levels above 65 mmHg without vasopressor influence. Yet, certain number of patients (36.2%) remains refractory to fluid administration, as seen in a retrospective study done on 3686 patients [23]. These patients often need prolonged mechanical ventilation and longer stay at ICU with higher death rate. The most common causes of refractoriness to fluid supplementation are: delay in fluid

administration after making diagnosis of sepsis (longer than 2 hours), the presence of heart failure as a comorbidity, hypothermia, coagulopathy, immunocompromised patients and serum lactate above 4 mmol/l at initial assessment of patients [23].

Rapid fluid renewal with satisfactory perfusion of vital organs aiming to correct MAP above the 65 mmHg, is essential for reanimation of critically ill patients and should not be delayed. If restoration of adequate tissue perfusion fails after initial fluid administration, vasopressor therapy, isolated or combined with inotropic drugs should be initiated. Physiological effects of both vasopressor and inotropic drugs are the rise of blood pressure and cardiac output and improvement of oxygen delivery to tissues. Vasopressor dose should be carefully titrated until desirable MAP level, having in mind potential risks for development of arrhythmia or cardiac, mesenteric, cerebrovascular and peripheral ischemia caused by these drugs [24]. Failure of vasopressors to correct blood pressure above desirable threshold (MAP > 65 mmHg), induces linear decline of tissue perfusion with significant reduction of hourly output of urine, with detrimental effect to mental status and lactate clearance [25]. Norepinephrine is the vasopressor of choice due to potent agonistic α -adrenergic effects and less potent β -adrenergic effects. Early administration of norepinephrine showed greater benefit in the treatment of septic shock due to better organ perfusion and reduced incidence of arrhythmias and mortality in these patients, compared to other vasopressors [26,27,28]. Immediate administration of norepinephrine (93 vs 192 minutes) after diagnosis of septic shock, was associated with better control of shock in the first 6 hours with reduced incidence of cardiogenic pulmonary oedema and newly arrhythmias compared to late administration of norepinephrine [29]. In order to implement this experience in everyday clinical practice, new studies with a higher degree of evidence are needed. Vasopressors other than norepinephrine such as: epinephrine, vasopressin, terlipressin or phenylephrine, may also be used [29,30]. Combined use of norepinephrine with any additional vasopressor may be applied if the isolated norepinephrine therapy was not able to achieve satisfactory MAP levels or if there is a risk for norepinephrine overdose (40 to 50 μ g/min) in

vazopresina, terlipresina ili fenilefrina [29,30]. Kombinovana primena norepinefrina i nekog od dodatnih vazopresora poput epinefrina se predlaže, ukoliko izolovana terapija norepinefrinom nije dovoljna u ostvarivanju zadovoljavajućeg MAP ili postoji opasnost od prekoračenja doze norepinefrina (40 - 50 µg/min) kod septičnih pacijenata. Iako postoje preporuke o kombinovanoj primeni norepinefrina i nekog od vazopresora, to se nije pokazalo efikasnim u studiji Zhou i sar. [31]. Primenom norepinefrina i vazopresina kod pacijenata sa sepsom i prethodno dijagnostikovanom srčanom insuficijencijom uočeno je slabije preživljavanje ovih pacijenata usled nastanka maligne aritmije u odnosu na pojedinačnu primenu norepinefrina ili dopamine [31]. Imajući u vidu navedene podatke, izbor odgovarajućeg vazopresora za lečenje septičnog šoka zahteva informaciju o prethodnim srčanim oboljenjima pre donošenja konačne odluke. Pored vazopresora, preporučuje se i primena inotropnih lekova, posebno kod pacijenata sa neadekvatnim minutnim volumenom srca nakon nadoknade tečnosti, usled nastanka sepsom indukovane kardiomiopatije ili postojanja kombinovanog šoka. Najčešće korišćeni inotropni lekovi su dobutamin i epinefrin [32,33]. Inotropi se mogu se koristiti pojedinačno ili kombinovano sa vazopresorima, mada kombinovana primena dobutamina i norepinefrina nije poboljšala mortalitet septičnih pacijenata niti skratila trajanje šoka u odnosu na pojedinačnu primenu epinefrina [33]. Efekti lečenja inotropima se moraju proveravati kroz procenu minutnog volumena srca, ScvO₂ i drugih parametara tkivne perfuzije.

ADJUVANTNA TERAPIJA KOD SEPTIČNIH PACIJENATA

Kortikosteroidi regulišu neadekvatan inflamatorni odgovor koji se sreće kod sepse i uzrokuju supresiju nadbubrežne žlezde ili povećavaju rezistenciju tkiva na glikokortikoide [34]. Kod pacijenata sa septičnim šokom, primena kortikosteroida može da smanji primenu vazopresora i redukuje trajanje šoka, mehaničke ventilacije kao i dužinu boravka u JIN. Ipak dosadašnji podaci nisu pokazali da primena kortikosteroida može poboljšati klinički ishod i preživljavanje pacijenata sa sepsom ili septičnim šokom, te se oni ne predlažu kod ovih pacijenata ukoliko su pacijenti adekvatno reagovali na nadoknadu tečnosti i vazopresore i

postigli hemodinamsku stabilnost [35,36,37]. Češće se dodaju kao pomoćna terapija kod pacijenata, koji zahtevaju više doze vazopresora [34]. Ukoliko se kortikosteroidi koriste, preporučuje se primena hidrokortizona u dozi od 200 mg za 24 sata kontinuirano ili 50 mg na 6 sati tokom sledeća 3 dana [38]. Sa primenom kortikosteroida uočena je značajna redukcija boravka u JIN i hospitalizacije, dok je 28-dnevni i ukupni mortalitet septičnih pacijenata redukovao sa umerenim stepenom dokaza. Rizik za pojavu velikih komplikacija nakon primene kortikosteroida je jako mali. Sa primenom kortikosteroida može se povećati rizik za nastanak mišićne slabosti, hipernatremije, a verovatno i rizik od hiperglikemije [39]. Neophodne su nove studije, koje će definisati kada će se započeti kortikosteroidna terapija u odnosu na početak šoka i koliko će ona trajati, a sve u odnosu na klinički ishod septičnih pacijenata.

Sa ordiniranjem intravenskih imunoglobulina kod septičnih pacijenata mogu se postići efekti neutralizacije antigena, blokiranja Fc-receptora na fagocitima i imunomodulacija citokinskog i celularnog odgovora [40]. Iako je u nekim studijama potvrđena klinička efikasnost intravenskih imunoglobulina u smislu redukcije hospitalnog mortaliteta septičnih pacijenata posebno kod njihovog ordiniranja u visokim dozama (1,5-2 g/kg), neophodna su dalja istraživanja u cilju pronalaženja novih i sigurnijih dokaza za njihovu široku primenu [41,42]. Druga studija ukazuje da je potrebno uključiti sledeće parametre u proceni kliničke efikasnosti intravenskih imunoglobulina tokom lečenja sepse i septičnog šoka kod pacijenata a to su: procena količine imunoglobulina koji se nalaze u ordiniranim preparatima, vremenskog perioda kada se imunoglobulini uključuju u odnosu na početak sepse (bolji su efekti sa njihovim uključivanjem unutar 24 sata od početka sepse), doze imunoglobulina u odnosu na stepen inflamacije i infekcije kod pacijenata sa sepsom [43]. Zbog čestih kontradiktornosti i slabih dokaza o primenljivosti imunoglobulina kod septičnih pacijenata, neophodna su dalja istraživanja u cilju rasvetljavanja efekata imunoglobulina.

Iako su brojni klinički trajali pokazali efikasnost antikoagulantne terapije kao adjuvantne terapije kod septičnih pacijenata, i dalje je malo dokaza da oni mogu redukovati

septic patients. In spite of these recommendations, combined treatment showed no efficacy in a study of Zhou et al. [31]. Combination of norepinephrine and vasopressin in septic patients with preexisting cardiac insufficiency was associated with inferior survival of these patients due to occurrence of malignant arrhythmia compared to monotherapy with either norepinephrine or dopamine [31]. Considering these data, the choice of proper vasopressor for the treatment of septic shock, requires obtaining additional information about preexisting heart problems, before reaching the final decision. Apart from vasopressors, inotropic drugs are recommended especially in patients with inadequate cardiac output after fluid supplementation due to sepsis-induced cardiomyopathy or existence of a combined shock. Most commonly used inotropic drugs are dobutamine and epinephrine [32,33]. Inotropic drugs may be given individually or in combination with vasopressors. It is worth saying that combined use of dobutamine with norepinephrine showed neither decrease in mortality nor influenced shock duration compared to sole administration of epinephrine [33]. Effects of inotropic drugs treatment must be checked through cardiac output, ScvO₂ or through measurements of other tissue perfusion parameters.

ADJUVANT THERAPY IN SEPTIC PATIENTS

Corticosteroids regulate inadequate inflammatory response that may be seen in sepsis and also may cause suprarenal gland insufficiency or may increase tissue resistance to glucocorticoids [34]. It is believed that in patients with septic shock, steroids may decrease the need for vasopressors and reduce the duration of a shock, the length of stay at ICU and duration of mechanical ventilatory support. So far, obtained results failed to prove any clinical benefit of corticosteroids on survival outcome for patients with sepsis or septic shock. For this reason, corticosteroids should not be given to septic patients, particularly if they achieve hemodynamic stability to fluid supplementation and vasopressors [35,36,37]. Corticosteroids are more frequently added as adjuvant therapy when there is a necessity for higher doses of vasopressors [34]. If the decision to use corticosteroids is made, recommended dose of hydrocortisone should be 200mg within 24 hours continuously or divided to 50mg every 6

hours through first three days [38]. With the administration of corticosteroids, the ICU and hospitalization stay was significantly reduced, while the 28-day and overall mortality of septic patients were reduced with moderate level of evidence. The risk of major complications occurrence, after corticosteroid use, was very low. Following its administration, one may also expect undesirable effects such as: muscle weakness, hyponatremia, and probably risk for hyperglycemia [39]. New studies are necessary in order to define proper timing and duration of corticosteroid treatment related to the beginning of septic shock, with close analysis of the patient's outcome.

With the administration of intravenous immunoglobulins in septic patients, the effects of antigen neutralization, blockade of Fc receptors on phagocytes and immunomodulation of the cytokine and cellular response can be achieved [40]. Although reduction of hospital mortality in septic patients after high doses (1.5-2 g/kg) of intravenous immunoglobulins, was observed in some studies, there are considerable limitations concerning these data, urging for stronger evidence before their use [41,42]. In order to get more adequate estimation of intravenous immunoglobulins efficacy in sepsis and septic shock, some authors suggest the need for analysis of additional parameters such as: the estimation of the amount of immunoglobulins present in administered drugs, timing of their administration related to sepsis onset (effects are better if immunoglobulins were given within 24 hours after sepsis onset), correlation between administered immunoglobulin dose and the degree of inflammation during infection [43]. Numerous contradictions and insufficient evidence about immunoglobulin efficacy in septic patients require further studies for the purpose of shedding light on immunoglobulin effects.

Even though numerous trials have shown efficacy of anticoagulant drugs in adjuvant treatment of septic patients, there is not much evidence about their benefit to mortality reduction in septic patients. The greatest benefit in anticoagulant use was noticed in patients with sepsis-induced disseminated intravascular coagulopathy [44].

Statin drugs administration has been associated with significant reduction in mortality of septic patients in certain

mortalitet ovih pacijenata. Najveći benefit u korišćenju antikoagulanasa je primećen kod pacijenata sa sepsom indukovanom diseminovanom intravaskularnom koagulopatijom [44].

Sa primenom statina u pojedinim opservacionim studijama je uočena značajna redukcija mortaliteta septičnih pacijenata u odnosu na randomizirane studije. Zbog toga su potrebna dalja istraživanja koja bi odgovorila na pitanje efikasnosti, bezbednosti i primenjene doze statina [45]. Pored toga, nagoveštava se značaj adjuvantne terapije poput rane aplikacije intravenskih vitamina C i B1 kod septičnog šoka, s obzirom na registrovan deficit ovih vitamina kod istih pacijenata. Iako rana aplikacija ovih vitamina nije poboljšala preživljavanje septičnih pacijenata, smatra se da uz standardne terapijske postupke može biti korisna kod ovih pacijenata [46,47].

ZAKLJUČAK

Lečenje pacijenata sa sepsom i septičnim šokom je izuzetno kompleksno, s obzirom na multifaktorijalnost sepse. Dobro poznavanje patofizioloških procesa, rano otkrivanje sepse i septičnog šoka, hitna i adekvatna nadoknada tečnosti unutar prvog sata od dijagnoze sepse uz primenu vazoaktivnih lekova u cilju postizanja hemodinamske stabilnosti, može biti presudno u obezbeđivanju boljeg ishoda ovih pacijenata. Adjuvantna terapija poput kortikosteroida, imunoglobulina, antikoagulantne terapije, statina, primene vitamina C i B1, imaju izvestan benefit u lečenju septičnih pacijenata, ali su potrebne dodatne kliničke studije i informacije, koje će sa većom preciznošću i sigurnošću potvrditi njihovu efikasnost.

LITERATURA:

- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-10.
- Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med*. 2017;43(3):304-377.
- Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. *Intensive Care Med*. 2018;44(6):925-928.
- Malbrain ML, Marik PE, Witters I, Kirkpatrick AW, Roberts DJ, Regenmortel NV, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. *Anaesthesiol Intensive Ther*. 2014;46(5):361-380.
- Vincent JL, De Backer D. Circulatory shock. *N Engl J Med*. 2013;369:1726-34.
- Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, et al. Balanced crystalloids versus saline in critically ill adults. *N Engl J Med*. 2018;378(9):829-839.
- Young P, Bailey M, Beasley R, Henderson S, Mackle D, McArthur C, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT Randomized Clinical Trial. *JAMA*. 2015;314(16):1701-1710.
- Krajewski ML, Raghunathan K, Paluszkiwicz SM, Schermer CR, Shaw AD. Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation. *Br J Surg*. 2015;102(1):24-36.
- Jiang L, Jiang S, Zhang M, Zheng Z, Ma Y. Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis. *PLoS One*. 2014;9(12):e114666.
- Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. *N Engl J Med*. 2012;367(2):124-134.
- Sakr Y, Rubatto Birri PN, Kotfi S K, Nanchal R, Shah B, Kluge S, et al. Higher fluid balance increases the risk of death from sepsis: results from a large international audit. *Crit Care Med*. 2017;45(3):386-394.
- Goldstein S, Bagshaw S, Cecconi M, Okusa M, Wang H, Kellum J, et al. Pharmacological management of fluid overload. *Br J Anaesth*. 2014;113:756-763.
- Frazee E, Kashani K. Fluid Management for Critically Ill Patients: A Review of the Current State of Fluid Therapy in the Intensive Care Unit. *Kidney Dis (Basel)*. 2016;2(2):64-71.
- Marik PE, Cavallazzi R: Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. *Crit Care Med*. 2013;41:1774-1781.
- Bednarczyk JM, Fridfinnson JA, Kumar A, Blanchard L, Rabbani R, Bellet D, et al. Incorporating dynamic assessment of fluid responsiveness into goal-directed therapy: a systematic review and meta-analysis. *Crit Care Med*. 2017;45(9):1538-1545.
- Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. *Crit Care Med*. 2009;37(9):2642-2647.
- Monnet X, Marik P, Teboul JL. Passive leg raising for predicting fluid responsiveness: a systematic review and meta-analysis. *Intensive Care Med*. 2016;42(12):1935-1947.
- Casserly B, Phillips GS, Schorr C, Dellinger RP, Townsend SR, Osborn TM, et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. *Crit Care Med*. 2015;43:567-573.
- Jansen TC, van Bommel J, Schoonderbeek FJ, Visser SJS, van der Klooster JM, Lima AP, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. *Am J Respir Crit Care Med*. 2010;182(6):752-761.

observational studies compared to randomized studies. For this reason, further studies should answer the questions concerning efficacy, safety and finding the adequate dose of statins in septic patients [45]. Many other aspects of adjuvant therapy in septic patients need clarifications. This is the case of the usefulness of early administration of intravenous vitamin C and B1 considering the registered deficiency of these vitamins in these patients. Although the early administration of these vitamins had no impact on overall survival of septic patients, it is considered that along with standard therapy vitamin supplementation may be beneficial in septic patients [46,47].

LITERATURE:

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-10.
2. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med*. 2017;43(3):304-377.
3. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. *Intensive Care Med*. 2018;44(6):925-928.
4. Malbrain ML, Marik PE, Witters I, Kirkpatrick AW, Roberts DJ, Regenmortel NV, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. *Anaesthesiol Intensive Ther*. 2014;46(5):361-380.
5. Vincent JL, De Backer D. Circulatory shock. *N Engl J Med*. 2013;369:1726-34.
6. Semler MW, Self WH, Wanderer JP, Ehrenfeld JM, Wang L, Byrne DW, et al. Balanced crystalloids versus saline in critically ill adults. *N Engl J Med*. 2018;378(9):829-839.
7. Young P, Bailey M, Beasley R, Henderson S, Mackle D, McArthur C, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT Randomized Clinical Trial. *JAMA*. 2015;314(16):1701-1710.
8. Krajewski ML, Raghunathan K, Paluszkievicz SM, Schermer CR, Shaw AD. Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation. *Br J Surg*. 2015;102(1):24-36.
9. Jiang L, Jiang S, Zhang M, Zheng Z, Ma Y. Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis. *PLoS One*. 2014;9(12):e114666.
10. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. *N Engl J Med*. 2012;367(2):124-134.
11. Sakr Y, Rubatto Birri PN, Kotfi S K, Nanchal R, Shah B, Kluge S, et al. Higher fluid balance increases the risk of

CONCLUSION

Treatment of patients with sepsis and septic shock is extremely complex, considering that sepsis is multifactorial. Good understanding of pathophysiological processes, early diagnosis of sepsis and septic shock, urgent and adequate fluid supplementation initiated within the first hour after the diagnosis with administration of vasoactive drugs aiming to achieve hemodynamic stability, may be crucial for better outcome of these patients. Adjuvant therapy like corticosteroids, immunoglobulins, anticoagulants or administration of vitamins C and B1, has some benefit in septic patients' treatment, but final decision about their use might be reached after collecting firm evidence from further clinical studies.

- death from sepsis: results from a large international audit. *Crit Care Med*. 2017;45(3):386-394.
12. Goldstein S, Bagshaw S, Cecconi M, Okusa M, Wang H, Kellum J, et al. Pharmacological management of fluid overload. *Br J Anaesth*. 2014;113:756-763.
13. Frazee E, Kashani K. Fluid Management for Critically Ill Patients: A Review of the Current State of Fluid Therapy in the Intensive Care Unit. *Kidney Dis (Basel)*. 2016;2(2):64-71.
14. Marik PE, Cavallazzi R: Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. *Crit Care Med*. 2013;41:1774-1781.
15. Bednarczyk JM, Fridfinnson JA, Kumar A, Blanchard L, Rabbani R, Bellet D, et al. Incorporating dynamic assessment of fluid responsiveness into goal-directed therapy: a systematic review and meta-analysis. *Crit Care Med*. 2017;45(9):1538-1545.
16. Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial waveform derived variables and fluid responsiveness in mechanically ventilated patients: a systematic review of the literature. *Crit Care Med*. 2009;37(9):2642-2647.
17. Monnet X, Marik P, Teboul JL. Passive leg raising for predicting fluid responsiveness: a systematic review and meta-analysis. *Intensive Care Med*. 2016;42(12):1935-1947.
18. Casserly B, Phillips GS, Schorr C, Dellinger RP, Townsend SR, Osborn TM, et al. Lactate measurements
- 158 sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. *Crit Care Med*. 2015;43:567-573.
19. Jansen TC, van Bommel J, Schoonderbeek FJ, Visser SJS, van der Klooster JM, Lima AP, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. *Am J Respir Crit Care Med*. 2010;182(6):752-761.
20. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA, et al. Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. *JAMA*. 2010;303:739-746.
21. Lyu X, Xu Q, Cai G, Yan J, Yan M. Efficacies of fluid resuscitation as guided by lactate clearance rate and

20. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA, et al. Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. *JAMA*. 2010;303:739–746.
21. Lyu X, Xu Q, Cai G, Yan J, Yan M. Efficacies of fluid resuscitation as guided by lactate clearance rate and central venous oxygen saturation in patients with septic shock. *Zhonghua Yi Xue Za Zhi*. 2015;95:496–500.
22. Hernández G, Ospina-Tascón GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. *JAMA*. 2019;321(7):654–664.
23. Leisman DE, Doerfler ME, Schneider SM, Masick KD, D'Amore JA, D'Angelo JK. Predictors, Prevalence, and Outcomes of Early Crystalloid Responsiveness Among Initially Hypotensive Patients With Sepsis and Septic Shock. *Crit Care Med*. 2018;46(2):189–198.
24. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. A randomised controlled trial of low dose vasopressin versus norepinephrine infusion in patients who have septic shock. *N Engl J Med*. 2008;17:877–887.
25. Leone M, Asfar P, Radermacher P, Vincent JL, Martin C. Optimizing mean arterial pressure in septic shock: a critical reappraisal of the literature. *Crit Care*. 2015;19:101.
26. Hamzaoui O, Scheeren TWL, Teboul JL. Norepinephrine in septic shock: when and how much? *Curr Opin Crit Care*. 2017;23(4):342–347.
27. De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. *Crit Care Med*. 2012;40(3):725–730.
28. Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and metaanalysis. *PLoS One*. 2015;10(8):e0129305.
29. Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. *Am J Respir Crit Care Med*. 2019;199(9):1097–1105.
30. Gamper G, Havel C, Arrich J, Losert H, Pace NL, Müllner M, et al. Vasopressors for hypotensive shock. *Cochrane Database Syst Rev*. 2016;2:CD003709.
31. Zhou D, Zhu B, Jiang J, Zhou G, Zhou S. Norepinephrine, Dopamine, and Vasopressin in Patients with Sepsis and Preexisting or Acute Heart Failure: A Retrospective Cohort Study. *Med Sci Monit*. 2021;27:e927716.
32. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med*. 2001;345(19):1368–1377.
33. Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. *Lancet*. 2007;370(9588):676–684.
34. Annane D, Pastores SM, Rochwerg B, Arlt W, Balk RA, Beishuizen A, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. *Crit Care Med*. 2017;45(12):2078–2088.
35. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. *N Engl J Med*. 2018;378(9):809–818.
36. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al. Adjunctive glucocorticoid therapy in patients with septic shock. *N Engl J Med*. 2018;378(9):797–808.
37. Rochwerg B, Oczkowski SJ, Siemieniuk RAC, Agoritsas T, Belley-Cote E, D'Aragon F, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. *Crit Care Med*. 2018;46(9):1411–1420.
38. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. *Cochrane Database Syst Rev*. 2015;2015(12):CD002243.
39. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y, et al. Corticosteroids for treating sepsis in children and adults. *Cochrane Database Syst Rev*. 2019;12(12):CD002243.
40. Kakoullis L, Pantzaris ND, Platanaki C, Lagadinou M, Papachristodoulou E, Velissaris D. The use of IgM-enriched immunoglobulin in adult patients with sepsis. *J Crit Care*. 2018;47:30–35.
41. Busani S, Damiani E, Cavazzuti I, Donati A, Girardis M. Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. *Minerva Anestesiol*. 2016;82(5):559–72.
42. Yang Y, Yu X, Zhang F, Xia Y. Evaluation of the Effect of Intravenous Immunoglobulin Dosing on Mortality in Patients with Sepsis: A Network Meta-analysis. *Clin Ther*. 2019;41(9):1823–1838.e4.
43. Aubron C, Berteau F, Sparrow RL. Intravenous immunoglobulin for adjunctive treatment of severe infections in ICUs. *Curr Opin Crit Care*. 2019;25(5):417–422.
44. Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. *J Thromb Haemost*. 2016;14(3):518–30.
45. Kruger PS, Venkatesh B. Are there any benefits from statin treatment for the septic patient? *Curr Atheroscler Rep*. 2014;16(1):378.
46. Shin TG, Kim YJ, Ryoo SM, Hwang SY, Jo IJ, Chung SP, et al. Early Vitamin C and Thiamine Administration to Patients with Septic Shock in Emergency Departments: Propensity Score-Based Analysis of a Before-and-After Cohort Study. *J Clin Med*. 2019;8(1):102.
47. Wilson JX. Evaluation of vitamin C for adjuvant sepsis therapy. *Antioxid Redox Signal*. 2013;19(17):2129–40.

- central venous oxygen saturation in patients with septic shock. *Zhonghua Yi Xue Za Zhi*. 2015;95:496–500.
22. Hernández G, Ospina-Tascón GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, et al. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28-day mortality among patients with septic shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. *JAMA*. 2019;321(7):654–664.
 23. Leisman DE, Doerfler ME, Schneider SM, Masick KD, D'Amore JA, D'Angelo JK. Predictors, Prevalence, and Outcomes of Early Crystalloid Responsiveness Among Initially Hypotensive Patients With Sepsis and Septic Shock. *Crit Care Med*. 2018;46(2):189–198.
 24. Russell JA, Walley KR, Singer J, Gordon AC, Hébert PC, Cooper DJ, et al. A randomised controlled trial of low dose vasopressin versus norepinephrine infusion in patients who have septic shock. *N Engl J Med*. 2008;17:877–887.
 25. Leone M, Asfar P, Radermacher P, Vincent JL, Martin C. Optimizing mean arterial pressure in septic shock: a critical reappraisal of the literature. *Crit Care*. 2015;19:101.
 26. Hamzaoui O, Scheeren TWL, Teboul JL. Norepinephrine in septic shock: when and how much? *Curr Opin Crit Care*. 2017;23(4):342–347.
 27. De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. *Crit Care Med*. 2012;40(3):725–730.
 28. Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and metaanalysis. *PLoS One*. 2015;10(8):e0129305.
 29. Permpikul C, Tongyoo S, Viarasilpa T, Trainarongsakul T, Chakorn T, Udompanturak S. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. *Am J Respir Crit Care Med*. 2019;199(9):1097–1105.
 30. Gamper G, Havel C, Arrich J, Losert H, Pace NL, Müllner M, et al. Vasopressors for hypotensive shock. *Cochrane Database Syst Rev*. 2016;2:CD003709.
 31. Zhou D, Zhu B, Jiang J, Zhou G, Zhou S. Norepinephrine, Dopamine, and Vasopressin in Patients with Sepsis and Preexisting or Acute Heart Failure: A Retrospective Cohort Study. *Med Sci Monit*. 2021;27:e927716.
 32. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med*. 2001;345(19):1368–1377.
 33. Annane D, Vignon P, Renault A, Bollaert PE, Charpentier C, Martin C, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. *Lancet*. 2007;370(9588):676–684.
 34. Annane D, Pastores SM, Rochwerf B, Arlt W, Balk RA, Beishuizen A, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. *Crit Care Med*. 2017;45(12):2078–2088.
 35. Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. *N Engl J Med*. 2018;378(9):809–818.
 36. Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al. Adjunctive glucocorticoid therapy in patients with septic shock. *N Engl J Med*. 2018;378(9):797–808.
 37. Rochwerf B, Oczkowski SJ, Siemieniuk RAC, Agoritsas T, Belley-Cote E, D'Aragn F, et al. Corticosteroids in sepsis: an updated systematic review and meta-analysis. *Crit Care Med*. 2018;46(9):1411–1420.
 38. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating sepsis. *Cochrane Database Syst Rev*. 2015;2015(12):CD002243.
 39. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y, et al. Corticosteroids for treating sepsis in children and adults. *Cochrane Database Syst Rev*. 2019;12(12):CD002243.
 40. Kakoullis L, Pantzaris ND, Platanaki C, Lagadinou M, Papachristodoulou E, Velissaris D. The use of IgM-enriched immunoglobulin in adult patients with sepsis. *J Crit Care*. 2018;47:30–35.
 41. Busani S, Damiani E, Cavazzuti I, Donati A, Girardis M. Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness. *Minerva Anesthesiol*. 2016;82(5):559–72.
 42. Yang Y, Yu X, Zhang F, Xia Y. Evaluation of the Effect of Intravenous Immunoglobulin Dosing on Mortality in Patients with Sepsis: A Network Meta-analysis. *Clin Ther*. 2019;41(9):1823–1838.e4.
 43. Aubron C, Berteau F, Sparrow RL. Intravenous immunoglobulin for adjunctive treatment of severe infections in ICUs. *Curr Opin Crit Care*. 2019;25(5):417–422.
 44. Umemura Y, Yamakawa K, Ogura H, Yuhara H, Fujimi S. Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials. *J Thromb Haemost*. 2016;14(3):518–30.
 45. Kruger PS, Venkatesh B. Are there any benefits from statin treatment for the septic patient? *Curr Atheroscler Rep*. 2014;16(1):378.
 46. Shin TG, Kim YJ, Ryoo SM, Hwang SY, Jo JJ, Chung SP, et al. Early Vitamin C and Thiamine Administration to Patients with Septic Shock in Emergency Departments: Propensity Score-Based Analysis of a Before-and-After Cohort Study. *J Clin Med*. 2019;8(1):102.
 47. Wilson JX. Evaluation of vitamin C for adjuvant sepsis therapy. *Antioxid Redox Signal*. 2013;19(17):2129–40.